Galvin Gaustad & Stein LLC Has $9.35 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Galvin Gaustad & Stein LLC lifted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 6.0% during the 4th quarter, HoldingsChannel reports. The fund owned 26,512 shares of the biotechnology company’s stock after acquiring an additional 1,505 shares during the quarter. Galvin Gaustad & Stein LLC’s holdings in United Therapeutics were worth $9,354,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Toronto Dominion Bank raised its holdings in United Therapeutics by 0.8% in the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after buying an additional 37 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock valued at $1,761,000 after buying an additional 39 shares in the last quarter. MBM Wealth Consultants LLC grew its stake in United Therapeutics by 1.9% in the fourth quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock valued at $775,000 after acquiring an additional 41 shares during the period. Benjamin F. Edwards & Company Inc. grew its stake in United Therapeutics by 14.0% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 42 shares during the period. Finally, First Citizens Bank & Trust Co. boosted its position in shares of United Therapeutics by 1.8% during the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock valued at $961,000 after buying an additional 48 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on UTHR shares. TD Cowen boosted their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Oppenheimer increased their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH increased their target price on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Argus raised their price target on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $378.36.

United Therapeutics Trading Down 0.3 %

Shares of UTHR stock opened at $370.00 on Thursday. The stock has a market capitalization of $16.52 billion, a price-to-earnings ratio of 16.25, a price-to-earnings-growth ratio of 0.94 and a beta of 0.57. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The stock’s 50-day moving average price is $365.33 and its 200-day moving average price is $355.12.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.38 earnings per share. As a group, research analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 7,800 shares of the company’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $350.00, for a total value of $2,730,000.00. Following the sale, the chief financial officer now directly owns 6,978 shares of the company’s stock, valued at approximately $2,442,300. This represents a 52.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Judy D. Olian sold 1,750 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $412.48, for a total transaction of $721,840.00. Following the sale, the director now directly owns 5,655 shares in the company, valued at approximately $2,332,574.40. The trade was a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 146,848 shares of company stock valued at $55,165,099 over the last 90 days. Corporate insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.